Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia (2024)
- Authors:
- Lima, Keli
- Nogueira, Frederico Lisboa
- Cipelli, Marcella
- Carvalho, Maria Fernanda Lopes
- Martins, Diego Antonio Pereira
- Silva, Wellington Fernandes da
- Medeiros, Rita de Cássia Cavaglieri
- Nardinelli, Luciana
- Leal, Aline de Medeiros
- Velloso, Elvira Deolinda Rodrigues Pereira
- Bendit, Israel
- Camara, Niels Olsen Saraiva
- Schuringa, Jan Jacob
- Machado Neto, João Agostinho
- Rego, Eduardo Magalhães
- Lima, Keli
- USP affiliated authors: VELLOSO, ELVIRA DEOLINDA RODRIGUES PEREIRA - FM ; BENDIT, ISRAEL - FM ; CÂMARA, NIELS OLSEN SARAIVA - ICB ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; REGO, EDUARDO MAGALHÃES - FM ; LIMA, KELI CRISTINA DE - FM ; NOGUEIRA, FREDERICO LISBOA - FM ; CIPELLI, MARCELLA - ICB ; CARVALHO, MARIA FERNANDA LOPES - ICB ; NARDINELLI, LUCIANA - FM
- Unidades: FM; ICB
- DOI: 10.1016/j.ejphar.2024.176723
- Subjects: FARMACOLOGIA; IMUNOLOGIA; ANTINEOPLÁSICOS; SOBREVIVÊNCIA CELULAR; INIBIDORES DE ENZIMAS; PROTEÍNAS QUINASES; PROTEÍNAS PROTO-ONCOGÊNICAS; NEOPLASIAS POR TIPO HISTOLÓGICO; LEUCEMIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: European Journal of Pharmacology
- ISSN: 1879-0712
- Volume/Número/Paginação/Ano: v. 977, art. 176723, 11 p., 2024
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
LIMA, Keli et al. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia. European Journal of Pharmacology, v. 977, p. 11 , 2024Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2024.176723. Acesso em: 01 abr. 2026. -
APA
Lima, K., Nogueira, F. L., Cipelli, M., Carvalho, M. F. L., Martins, D. A. P., Silva, W. F. da, et al. (2024). Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia. European Journal of Pharmacology, 977, 11 . doi:10.1016/j.ejphar.2024.176723 -
NLM
Lima K, Nogueira FL, Cipelli M, Carvalho MFL, Martins DAP, Silva WF da, Medeiros R de CC, Nardinelli L, Leal A de M, Velloso EDRP, Bendit I, Camara NOS, Schuringa JJ, Machado Neto JA, Rego EM. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia [Internet]. European Journal of Pharmacology. 2024 ; 977 11 .[citado 2026 abr. 01 ] Available from: https://doi.org/10.1016/j.ejphar.2024.176723 -
Vancouver
Lima K, Nogueira FL, Cipelli M, Carvalho MFL, Martins DAP, Silva WF da, Medeiros R de CC, Nardinelli L, Leal A de M, Velloso EDRP, Bendit I, Camara NOS, Schuringa JJ, Machado Neto JA, Rego EM. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia [Internet]. European Journal of Pharmacology. 2024 ; 977 11 .[citado 2026 abr. 01 ] Available from: https://doi.org/10.1016/j.ejphar.2024.176723 - Impact of Ph-like gene signatures on clinical outcomes in adult B-all patients in Resource-Constrained settings
- Clinical significance of Philadelphia-like-related genes in a resource-constrained setting of adult B-acute lymphoblastic leukemia patients
- Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia
- Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia
- Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities
- Pharmacological inhibition of ezrin reduces proliferative and invasive phenotype in acute lymphoblastic leukemia cells
- Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways
- Comprehensive analysis of the HCK gene in myeloid neoplasms: insights into biological functions, prognosis, and response to antineoplastic agents
- Overcoming acquired venetoclax resistance in acute myeloid leukemia through cell metabolism targeting
- Gut microbiota resilience mechanisms against pthogen infection and its role in infammatory Bowel Disease
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
